Nucleotide metabolism disorders

Gene: AMPD2

Green List (high evidence)

AMPD2 (adenosine monophosphate deaminase 2, Ensemblv115)
EnsemblGeneIds (GRCh38): ENSG00000116337
EnsemblGeneIds (GRCh37): ENSG00000116337
OMIM: 102771, ClinGen, DECIPHER
AMPD2 is in 24 panels

1 review

Zornitza Stark (Victorian Clinical Genetics Services)

Green List (high evidence)

Well established gene-disease association. Clinical features include severely delayed psychomotor development, progressive microcephaly, spasticity, seizures, and brain abnormalities, including brain atrophy, thin corpus callosum, and delayed myelination.
Created: 18 Sep 2021, 11:57 a.m. | Last Modified: 18 Sep 2021, 11:57 a.m.
Panel Version: 0.9186

Mode of inheritance
BIALLELIC, autosomal or pseudoautosomal

Phenotypes
Pontocerebellar hypoplasia, type 9, MIM#615809

Publications

History Filter Activity

20 May 2024, Gel status: 3

Created, Added New Source, Set mode of inheritance, Set publications, Set Phenotypes

Bryony Thompson (Royal Melbourne Hospital)

gene: AMPD2 was added gene: AMPD2 was added to Nucleotide metabolism disorders. Sources: Expert Review Green Mode of inheritance for gene: AMPD2 was set to BIALLELIC, autosomal or pseudoautosomal Publications for gene: AMPD2 were set to 27066553; 23911318 Phenotypes for gene: AMPD2 were set to pontocerebellar hypoplasia type 9 MONDO:0014351; Disorders of purine metabolism